Research
Hormonal
Ovulatory dysfunction in PCOS is associated with elevated levels of serine, threonine, phenylalanine, tyrosine, and ornithine, suggesting that increased ovarian uptake of these amino acids contributes to anovulation.
If you struggle with anovulation, your body's handling of certain amino acids (serine, threonine, etc.) might be a key factor. This insight can help fertility specialists design more targeted treatments to support ovulation, addressing the metabolic root cause alongside hormonal therapies.
GoodSupportsHIGH confidence
Ovulatory dysfunction of PCOS patients was associated with raised production of serine, threonine, phenylalanine, tyrosine and ornithine.
Why this rating
Consistent findings across anovulatory PCOS subgroups.
Source
Metabolic profiles characterizing different phenotypes of polycystic ovary syndrome: plasma metabolomics analysis
Yue Zhao et al. · BMC Medicine · 2012
DOI 10.1186/1741-7015-10-153
cross_sectional · n=265Cited 218×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Women with polycystic ovary syndrome (PCOS) exhibit a distinct metabolic profile characterized by elevated lactate, long-chain fatty acids, and specific amino acids (valine, leucine, serine, threonine, phenylalanine, tyrosine, ornithine), alongside reduced glucose, glycine, and proline, which serves as a biomarker for insulin resistance and diabetes risk.Good
- A reduced ratio of branched-chain amino acids (BCAA) to aromatic amino acids (AAA) in plasma is a specific metabolic signature of PCOS that is independent of obesity and insulin resistance, distinguishing it from type 2 diabetes profiles.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →